This site is intended only for all Healthcare Professionals residing in South Africa
Menu
Close
Menu
Close
The primary end points were the proportion of patients who had an ACR20a response at month 3 and the change from baseline in HAQDIb score at month 3.1
In a 12-month, double-blind, active-controlled and placebo-controlled phase 3 trial that evaluated XELJANZ® (tofacitinib) in patients with active PsA who previously had an inadequate response to csDMARDs: 318 patients were randomised to receive one of the following regimens: XELJANZ® (tofacitinib) at a 5 mg dose taken orally twice daily (107 patients), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106) or placebo (105). Placebo groups were pooled for analyses up to month 3.1
The primary end points were an ACR20a response and the change from baseline score on the HAQ-DIb score at the month 3 analysis.2
In a 6-month randomized, placebo-controlled, double-blind, phase 3 trial evaluated XELJANZ® (tofacitinib) in patients with active psoriatic arthritis who had previously had an inadequate response to TNFis: 262 patients were randomised to: 5 mg of XELJANZ® (tofacitinib) administered orally twice daily (131) or placebo (131). Data from the patients who received placebo during the first 3 months of the trial were pooled.2
Copyright ©2024 Pfizer South Africa All rights reserved.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.
This website is brought to you by Pfizer South Africa
Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).
Copyright © 2024. Pfizer Laboratories (Pty) Ltd. All rights reserved
These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.
I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.